*

Hitt og þetta 16. ágúst 2006

Share Buyback in H. Lundbeck A/S

Acting on its authorization to acquire up to 10% of its shares the H. Lundbeck Supervisory Board has resolved to initiate a share buyback program. Under the program H. Lundbeck will buy own shares for an amount of up to DKK 6 billion until end of 2007, cf. stock exchange announcement number 166 on 17th August 2005.

During any one single trading day a maximum of 25% of the average daily trading volume of Lundbeck shares on the Copenhagen Stock Exchange, calculated over 20 days prior to each trading date, will be bought back, as the share buyback program is implemented in accordance with the provisions of the European Commission's regulation no. 2273/2003 of December 22, 2003.

At least once every seven trading days, Lundbeck will issue an announcement in respect of the transactions made under the program.

The following transactions have been made under the program:

No. of shares Average Transaction value purchase price (DKK) (DKK) Accumulated, last 15,320,719 134.2794 2,057,257,273 announcement 8 August 2006 67,889 140.4564 9,535,446 9 August 2006 67,889 138.5752 9,407,729 10 August 2006 - - - 11 August 2006 - - - 14 August 2006 - - - 15 August 2006 - - - 16 August 2006 76,035 133.9702 10,186,425 Accumulated under the 15,532,532 134.3237 2,086,386,874 program

Following the above buyback Lundbeck owns a total of 2,243,389 own shares at a nominal value of DKK 5, equal to 1.06% of the total number of 211,760,805 shares.

The content of this release will have no influence on the Lundbeck Group's financial result for 2006.

Lundbeck contacts

Steen Juul Jensen Vice President +45 36 43 30 06

Media Caroline Broge Investor Jacob Tolstrup contact Media Relations Manager contact Investor Relations Manager +45 36 43 26 38 +45 36 43 30 79

________________________

About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2005, the company's revenue was DKK 9.1 billion (approximately EUR 1.2 billion or USD 1.5 billion). The number of employees is approximately 5,000 globally. For further information, please visit www.lundbeck.com